dexmedetomidine has been researched along with Cardiotoxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, XY; Gu, HH; Jin, Y; Yu, JL | 1 |
| Cai, X; Cai, Y; Chen, H; Jin, Z; Lin, T; Pan, L; Wang, S; Xia, F | 1 |
2 other study(ies) available for dexmedetomidine and Cardiotoxicity
| Article | Year |
|---|---|
Dexmedetomidine alleviates doxorubicin cardiotoxicity by inhibiting mitochondrial reactive oxygen species generation.
Topics: Adrenergic Agonists; Animals; Cardiotoxicity; Dexmedetomidine; Doxorubicin; Mice; Mice, Inbred C57BL; Mitochondria; Reactive Oxygen Species | 2020 |
Dexmedetomidine enhances tolerance to bupivacaine cardiotoxicity in the isolated rat hearts: alpha 2 adrenoceptors were not involved.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Non-Narcotic; Anesthetics, Local; Animals; Bupivacaine; Cardiotoxicity; Dexmedetomidine; Drug Tolerance; Heart; In Vitro Techniques; Male; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 2019 |